Literature DB >> 19380026

Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.

Carmen Franco-Hernández1, Victor Martínez-Glez, Jose M de Campos, Alberto Isla, Jesús Vaquero, Manuel Gutiérrez, Cacilda Casartelli, Juan A Rey.   

Abstract

Identification of the 1p/19q allelic status in gliomas, primarily those with a major oligodendroglial component, has become an excellent molecular complement to tumor histology in order to identify those cases sensitive to chemotherapy. In addition to loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), or comparative genomic hybridization (CGH), multiplex ligation-dependent probe amplification (MLPA) has been shown to be an alternative methodology to identify deletions of those chromosome arms. We used MLPA to explore the 1p and 19q allelic constitution in a series of 76 gliomas: 41 tumors with a major oligodendroglial component, 34 glioblastomas, and one low-grade astrocytoma. We compared the MLPA findings of the oligodendroglial cases with those previously obtained using LOH in the same samples. Thirty-eight of 41 oligodendrogliomas displayed identical findings by both LOH and MLPA, and losses at either 1p and/or 19q were identified in 12 of 35 (34%) astrocytic tumors. These findings agree with data previously reported comparing MLPA versus FISH or CGH in gliomas and suggest that MLPA can be used in the identification of the 1p/19q allelic deletions on these brain neoplasms.

Entities:  

Mesh:

Year:  2009        PMID: 19380026     DOI: 10.1016/j.cancergencyto.2008.09.017

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Authors:  Benedikt Wiestler; David Capper; Volker Hovestadt; Martin Sill; David T W Jones; Christian Hartmann; Joerg Felsberg; Michael Platten; Wolfgang Feiden; Kathy Keyvani; Stefan M Pfister; Otmar D Wiestler; Richard Meyermann; Guido Reifenberger; Thorsten Pietsch; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-07-15       Impact factor: 12.300

3.  Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.

Authors:  Anna Latysheva; Kyrre Eeg Emblem; Petter Brandal; Einar Osland Vik-Mo; Jens Pahnke; Kjetil Røysland; John K Hald; Andrés Server
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

Review 4.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

5.  The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jonathan Hobbs; Stephanie Bortoluzzi; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

Review 6.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

7.  Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue-a glioma-driven study.

Authors:  Kim Van der Eecken; Malaïka Van der Linden; Lennart Raman; David Creytens; Franceska Dedeurwaerdere; Koen De Winne; Liesbeth Ferdinande; Martin Lammens; Björn Menten; Isabelle Rottiers; Bram Van Gaever; Caroline Van den Broecke; Koen Van de Vijver; Nadine Van Roy; Sofie Verbeke; Jo Van Dorpe
Journal:  Virchows Arch       Date:  2022-01-16       Impact factor: 4.535

Review 8.  Epidemiologic and molecular prognostic review of glioblastoma.

Authors:  Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

9.  Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.

Authors:  Umma Habiba; Hirokazu Sugino; Roumyana Yordanova; Koki Ise; Zen-Ichi Tanei; Yusuke Ishida; Satoshi Tanikawa; Shunsuke Terasaka; Ken-Ichi Sato; Yuuta Kamoshima; Masahiko Katoh; Motoo Nagane; Junji Shibahara; Masumi Tsuda; Shinya Tanaka
Journal:  Acta Neuropathol Commun       Date:  2021-05-21       Impact factor: 7.578

Review 10.  Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases.

Authors:  Liborio Stuppia; Ivana Antonucci; Giandomenico Palka; Valentina Gatta
Journal:  Int J Mol Sci       Date:  2012-03-08       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.